DS Healthcare Group obtains regulatory approval in Middle East

Pompano Beach, Fla., Sept. 4, 2014 (GLOBE NEWSWIRE) -- This agreement comes on the heels of the Company's recent expansion into Brazil and China. International sales are a key driver of the Company's growth, as its breakthrough products are in high demand in Canada, Mexico, the UK, and Australia.

According to Euromonitor, the Middle East's beauty sector is worth between $1.5 billion and $2 billion per year, which is equivalent to about 6% of the $255 billion worldwide market.

"As a business and cultural hub for the Middle East, UAE is a great location through which to introduce our DS Laboratories product line into the region. This represents a significant growth opportunity for us," stated DS Healthcare President and CEO Daniel Khesin.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Healthcare Group's flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.

CONTACT: Laurel Moody Corporate Profile 1.646.810.0608

Source:DS Healthcare Group,Inc.